PRESS RELEASE published on 05/20/2026 at 20:45, 5 months 14 days ago Inside Information / Other news releases MaaT Pharma receives a 'negative trend' opinion from CHMP for their Marketing Authorization Application of MaaT013 (Xervyteg) in acute Graft-versus-Host Disease treatment. Company plans re-examination procedure MaaT Pharma CHMP Marketing Authorization Negative Trend Re-examination
BRIEF published on 04/21/2026 at 15:14, 6 months 12 days ago MaaT Pharma SACA Maintains Buy Rating with Stable Financial Outlook Financial Performance BUY Rating Pipeline Development MaaT Pharma Investment Case
PRESS RELEASE published on 04/21/2026 at 15:09, 6 months 12 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research reaffirms Buy rating for MaaT Pharma SACA with a target price of €17 following FY25 results and pipeline update. No changes to core investment case First Berlin Equity Research BUY Rating MaaT Pharma SACA FY25 Results €17 Target Price
BRIEF published on 04/01/2026 at 07:35, 7 months 3 days ago MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
BRIEF published on 04/01/2026 at 07:35, 7 months 3 days ago MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy
PRESS RELEASE published on 04/01/2026 at 07:30, 7 months 3 days ago Inside Information / Other news releases MaaT Pharma announces publication of retrospective data from CHRONOS study in Bone Marrow Transplantation Journal, presenting real-world outcomes of third-line systemic treatments for GI-aGvHD patients MaaT Pharma GI-aGvHD CHRONOS Study Retrospective Data Bone Marrow Transplantation
BRIEF published on 03/31/2026 at 07:35, 7 months 4 days ago MaaT Pharma: 2025 Revenue and Clinical Progress Revenue Funding Clinical Development MaaT Pharma Microbiothérapies
BRIEF published on 01/20/2026 at 18:35, 9 months 14 days ago MaaT Pharma Launches Phase 2 Trial for NSCLC Patients NSCLC MaaT Pharma Gut Microbiome IMMUNOLIFE Phase 2 Antibiotic-induced Dysbiosis
PRESS RELEASE published on 01/20/2026 at 18:30, 9 months 14 days ago Inside Information / Other news releases MaaT Pharma announces first patient randomized in IMMUNOLIFE Phase 2 study sponsored by Gustave Roussy to explore the role of gut microbiome in overcoming ICI resistance in NSCLC patients with antibiotic-induced dysbiosis NSCLC MaaT Pharma Gut Microbiome Antibiotic-induced Dysbiosis IMMUNOLIFE
BRIEF published on 12/10/2025 at 11:30, 10 months 24 days ago MaaT Pharma SACA Maintains Positive Outlook as Phase 3 Trial Data Strengthens Buy Recommendation Phase 3 Trial MaaT Pharma Xervyteg GI-aGvHD
Published on 11/04/2026 at 00:05, 9 hours 50 minutes ago Scoping Study Begins for High-Grade Underground Mine Feed
Published on 11/04/2026 at 00:00, 9 hours 55 minutes ago RE Royalties Launches $5 Million Series 5 Green Bond Offering and Provides Strategic Growth Update
Published on 11/03/2026 at 23:30, 10 hours 25 minutes ago AT&T and Amdocs Expand Collaboration, Bringing Together Amdocs aOS and AT&T's AI-Enabled Framework to Simplify Operations and Improve Customer Experiences
Published on 11/03/2026 at 23:30, 10 hours 25 minutes ago GGL Resources Corp. Issues Post-Consolidation Shares to Strategic Metals Ltd.
Published on 11/04/2026 at 09:15, 40 minutes ago Fox ESS Signs Youngest Porsche Carrera Cup Germany Winner, Champion On and Off the Track
Published on 11/04/2026 at 09:15, 40 minutes ago Omnissa expands Sovereign Solution to more markets, designed to give enterprises a safe place to run AI
Published on 11/04/2026 at 09:05, 50 minutes ago New global Mouth-to-Body Health Institute aims to turn oral-systemic science into better prevention and care
Published on 11/04/2026 at 09:00, 55 minutes ago Original-Research: GFT Technologies SE (von NuWays AG): BUY
Published on 11/04/2026 at 09:00, 55 minutes ago Original-Research: CEOTRONICS AG (von NuWays AG): BUY
Published on 11/03/2026 at 18:00, 15 hours 55 minutes ago Outstanding Shares and Voting Rights Monthly Statement - 31 October 2026
Published on 11/03/2026 at 17:45, 16 hours 10 minutes ago Declaration of voting rights at the end of October 2026
Published on 11/02/2026 at 18:30, 1 day 15 hours ago Disclosure of transactions in own shares from October 26 to October 30, 2026
